Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment

Abstract

Aim. To compare efficacy and safety of warfarin and enoxaparin used in the first month of treatment of patients with an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE).
Material and methods. Sixty patients (34 males, 26 females, age 18-76 years) after the DVT/PATE episode were divided into two groups. Patients of group 1 received standard therapy (non-fractionated heparin -NFH followed by warfarin), patients of group 2 instead of NFH received enoxaparin (1 mg/ kg each 12 hours for at least 30 days). Ultrasonic scanning of the limbs and determination of D-dimer were conducted before and after 1 month of treatment. End points were the following: recurrent DVT/ PATE, death due to PATE, hemorrhagic complications.
Results. Improvement of deep vein patency after 1 month of anticoagulant treatment was observed in both the groups. Enoxaparin proved more effective in relation to reduction of the number of venous occlusions (9 and 50, respectively, after 1 month treatment (p < 0.001). Hemorrhagic complications were seen in both the groups with equal frequency (13.4%). These hemorrhagic episodes did not require discontinuation of the drugs. Baseline D-dimer was significantly higher in the enoxaparin group - 1.51 (0.73-2.44) mcg/ml vs 0.93 (0.42-1.33) mcg/ml (p = 0.019). After treatment D-dimer level and number of patients with high D-dimer diminished in both groups.
Conclusion. Enoxaparin proved more effective than warfarin in the first treatment month. In the same safety and prophylactic effect enoxaparin is more effective in recanalization of occusions in the deep veins.

References

  1. Kearon С., Kahn S. R., Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (suppl.): 454S-545S.
  2. Lee A. Y., Levine M. N., Baker R. I. et al. Low-molecular-weight heparin versus a coumarin for prevention of recurrent venous thromboembolism in patient with cancer. N. Engl. J. Med. 2003; 349: 146-153.
  3. Fihn S. D., McDonell M., Martin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann. Intern. Med. 1993; 118: 511-520.
  4. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903-1912.
  5. Prandoni P., Carnovali M., Marchiori A. Subcutaneous adjusted-dose unfractionated heparin versus fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch. Intern. Med. 2004; 164: 1077-1083.
  6. Kearon C., Ginsberg J. S., Julian J. A. et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. J. A. M. A. 2006; 296: 935-942.
  7. Lopaciuk S., Meissner A. J., Filipecki S. et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb. Haemost. 1992; 68: 14-18.
  8. Faivre R., Neuhart Y., Keiffer Y. et al. A new treatment of deep venous thrombosis: low molecular weight heparin fraction; randomized study. Presse Med. 1988; 17: 197-200.
  9. Pini M., Aiello S., Manotti C. et al. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis. Thromb. Haemost. 1994; 72: 191-197.
  10. Gonzalez-Fajardo J. A., Arreba E., Castrodeza J. et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J. Vasc. Surg. 1999; 30: 283-292.
  11. Meyer G., Marjanovic Z., Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patient with cancer. Arch. Intern. Med. 2002; 162: 1729-1735.
  12. Viega F., Escriba A., Maluenda M. P. et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-564.
  13. Iorio A., Guercini F., Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulant. Thromb. Haemost. 2003; 1: 1906- 1913.
  14. van der Heijden J. F., Hutten B. A., Buller H. R. et al. Vitamin К antagonists or low molecular weight heparin for the long term treatment of symptomatic venous thromboembolism. (Cochrane Review). The Coch-rane Library 2002; Issue 4.
  15. Hull R., Pineo G. F., Mah A. et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. Blood 2002; 100: 148a.
  16. Hull R., Pineo G. F., Mah A. et al. Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract]. Thromb. Haemost. 2001; suppl.: abstr. ОС1647.
  17. Bajzar L., Nesheim M. E., Tracy P. B. The profibrinolytic effect of activated protein С in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
  18. Ninet J., Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of DVT. A collaborative European multicentre study. Thromb. Haemost. 1991; 65: 251-255.
  19. Simonneau G., Charbonnier В., Decousus H. et al. Subcutaneous low-molecular-weight heparin compared with continuous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch. Intern. Med. 1993; 153: 1541-1546.
  20. Schulman S., Beyth R. J., Kearon C. et al. Hemorrhagic complication of anticoagulant and thrombolytic treatment. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (suppl): 257S- 298S.
  21. Timinski U., Rabe E. Results of the D-dimer test during the anticoagulation therapy of deep vein thrombosis. Vasomed 1999; suppl. 1: 49.
  22. Elias A., Bonfils S., Daoud-Elias M. et al. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb. Haemost. 1993; 69: 302-305.
  23. Eichinger S., Minar E., Bialonczyk C. et al. D-dimer levels and risk of recurrent venous thromboembolism. J. A. M. A. 2003; 290: 1071-1074.
  24. Fattorini A., Crippa L., Vigano D'Angelo S. et al. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb. Haemost. 2002; 88: 162-163.
  25. de Bastos M., Bogutchi T., Carneiro-Proietti A. B. F. et al. Duration of symptoms and D-dimer testing in the ruling-out of venous thromboembolism. Thromb. Haemost. 2006; 4: 2079- 2080.

Statistics

Views

Abstract: 246

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Vorob'eva N.M., Panchenko E.P., Kirienko A.I., Dobrovol'skiy A.B., Titaeva E.V., Ermolina O.V., Balakhonova T.V., Andriyashkin V.V., Leont'ev S.G., Vorobieva N.M., Panchenko E.P., Kirienko A.I., Dobrovolsky A.B., Titaeva E.B., Ermolina O.V., Balakhonova T.V., Andriyashkin V.V., Leotiev S.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies